Infectious Disease Control
GC Biopharma Receives WHO Pre-Qualification for BARYCELA
YONGIN, South Korea, Feb. 19, 2023 /PRNewswire/ -- GC Biopharma (006280.KS), a leading provider of biopharmaceutical products inSouth Korea, announced today that the World Health Organization (WHO) has granted prequalification for BARYCELA, GC Biopharma's varicella vaccine. WHO prequalificatio...
2023-02-20 09:38
1733
Global Times: Small and mid-sized cities in China go through infection peak, bearing new hope for future
BEIJING, Feb. 1, 2023 /PRNewswire/ -- As media sources around the world have paid so much attention to infection surges in various metropolises or first-and-second-tier cities inChina and governments at all levels have attached great importance to anti-epidemic work in rural areas, a review on ho...
2023-02-01 22:45
2088
Global Times: Having weathered epidemic storms overseas, Chinese return to hometown for safe, joyous Spring Festival reunions
BEIJING, Jan. 31, 2023 /PRNewswire/ -- Red lanterns are once again hung in the contemporary houses that combine Chinese and Western elements in the famous hometown of overseas Chinese in East China'sFujian Province. For countless overseas Chinese, this year's Spring Festival provided an opportun...
2023-01-31 22:10
2125
Global Times: 'So much better than we had anticipated': China's rural regions embrace Spring Festival as COVID peak ebbs away
BEIJING, Jan. 31, 2023 /PRNewswire/ -- The Spring Festival is rooted in agricultural civilization. Chinese people believe the most traditional atmosphere of Spring Festival is in rural regions. Since the prevention and control of the COVID-19 epidemic has entered a new stage, questions have been...
2023-01-31 21:41
2080
SK bioscience Introduces New Partnership Model to Establish Regional Vaccine Hubs
* SK bioscience shared a development history of the South Korea's first COVID-19 vaccine at the Riyadh Global Medical Biotechnology Summit 2023 (RGBMS 2023) in theKingdom of Saudi Arabia(KSA) * SK bioscience also explained a new global partnership model aiming to promote public health in deve...
2023-01-27 20:00
3769
Looking Back on Three Years of COVID-19 in China
BEIJING, Jan. 13, 2023 /PRNewswire/ -- A news report from Beijing Review:
2023-01-13 22:29
3754
Global Times: Connected in recognition: Foreign ambassadors signal a welcome for China's optimized, responsible COVID policy
BEIJING, Jan. 11, 2023 /PRNewswire/ -- As of January 8, China downgraded the management of COVID-19 from category A to the less serious category B infectious disease in light of the evolving epidemic. The Chinese government has optimized measures to combat the epidemic in accordance with the soci...
2023-01-11 18:24
1804
Global Times: 'Zhang Wenhong phenomenon' shows inclusiveness of China's public opinion sphere; policymaking based on science helps nation firmly hold strategic initiative of epidemic fight
BEIJING, Jan. 11, 2023 /PRNewswire/ -- On Friday, China released the 10th edition of the COVID-19 prevention and control protocol. Moreover, starting from Sunday, the country downgraded the management of COVID-19 from Class A to Class B and lifted quarantine requirements for inbound travelers. Th...
2023-01-11 17:49
1595
Global Times: China shifts COVID policy with necessary conditions
BEIJING, Jan. 5, 2023 /PRNewswire/ -- After three years' hard efforts to keep COVID-19 at bay,China has optimized its virus response and come up with a major shift in its epidemic policy by downgrading COVID management and announcing the reopening of international borders fromJanuary 8, 2023. Glo...
2023-01-05 23:21
1822
China enters new stage in COVID-19 response
BEIJING, Dec. 29, 2022 /PRNewswire/ -- A news report by China.org.cn on China's COVID-19 response:   Changes are taking place to China's COVID-19 response. Now, efforts are being accelerated across the country to fully reopen the economy, and people are generally no longer requ...
2022-12-29 22:00
2279
Global Times: Three years' hard effort to fight COVID-19 'worthwhile'
BEIJING, Dec. 28, 2022 /PRNewswire/ -- After three years' hard effort to keep the COVID-19 at bay,China has optimized its virus responses recently. The Global Times has talked with front line medical workers, grass-roots community workers and others about their experience in the three-year battle...
2022-12-28 21:38
1983
PHASE II/III CLINICAL TRIAL OF SIMCERE'S 3CL-TARGETING ANTI-SARS-COV-2 DRUG CANDIDATE COMPLETE ALL PATIENTS ENROLLMENT
NANJING, China, Dec. 20, 2022 /PRNewswire/ -- Simcere Pharmaceutical Group (2096.HK) announced today that, XIANNUOXIN (SIM0417), an anti-SARS-CoV-2 drug candidate jointly developed by Simcere with Shanghai Institute ofMateria Medica (the "SIMM") and Wuhan Institute of Virology (the "WIV"), Chines...
2022-12-20 19:21
1800
E-Home Household Services Holdings Limited's subsidiary Zhong Run Launches Cloud Pharmacy Service to Address New Situation of Epidemic Prevention and Control
FUZHOU, China, Dec. 14, 2022 /PRNewswire/ -- E-Home Household Service Holdings Limited (Nasdaq: EJH) (the "Company" or "E-Home"), a provider of integrated household services inChina, today announced that the Company's subsidiary Zhongrun (Fujian) Pharmaceutical Co., Ltd. ("Zhongrun") plan to expa...
2022-12-14 21:30
2431
Epidemic: Modified approach ensures maximum benefit
BEIJING, Dec. 12, 2022 /PRNewswire/ -- A report from chinadaily.com.cn:
After three years of battling COVID-19, experts said China is seeing the
light at the end of the tunnel as it continues to optimize measures against the
epidemic.
2022-12-13 11:42
1485
Program CD47, provided the CMC service by GenScript ProBio to InnobationBio, will further be advanced by the joint venture between Liminatus Pharma LLC and Iris Acquisition Corp
NEW YORK and LONDON, Dec. 5, 2022 /PRNewswire/ -- Recently, Liminatus Pharma LLC ("Liminatus"), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies and Iris Acquisition Corp ("Iris") (Nasdaq: IRAA), a publicly traded special purpose acquisition company ...
2022-12-05 20:00
1365
Comirnaty Bivalent Vaccine Arrives in Hong Kong SAR and Macau SAR and Will Soon Be Available to the Local Residents
SHANGHAI, Nov. 28, 2022 /PRNewswire/ -- On November 26, 2022, Shanghai Fosun Pharma (Group) Co., Ltd.("Fosun Pharma", Stock Code: 600196.SH; 02196.HK) announced that the first batch of about 770,000 doses of the Comirnaty Original/Omicron BA.4/BA.5 bivalent vaccine (i.e. Comirnaty Original/Omicro...
2022-11-28 22:59
3822
Immorna Receives IND Clearance to Conduct a Phase 1/2 Study of JCXH-221, a Broadly Protective mRNA-Based COVID-19 Vaccine
MORRISVILLE, N.C., Nov. 21, 2022 /PRNewswire/ -- Immorna, a rapidly expanding biotechnology company, focusing on the development of multi-platform RNA-based therapeutics and vaccines, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) a...
2022-11-21 20:00
1629
WuXi Vaccines Establishes New Vaccines CDMO Facility in China
SUZHOU, China, Nov. 15, 2022 /PRNewswire/ -- WuXi Vaccines, a leading global Contract Development and Manufacturing Organization (CDMO), announced that it has entered into an agreement with Harbour BioMed under which Harbour BioMed's manufacturing facility in Suzhou will be transferred to WuXi Va...
2022-11-15 12:45
1652
Traditional Chinese Medicine Lianhua Qingwen Attracted Eyes in the Annual National Conference of Pharmaceutical Society of Nigeria
SHIJIAZHUANG, China, Nov. 8, 2022 /PRNewswire/ -- Recently, the 95th National Annual Conference of the Pharmaceutical Society ofNigeria was held in Jos, capital of Plateau State. The theme of the Conference in this year was "Medicine Security in an Unstable Economy", and more than 3,000 doctors a...
2022-11-08 20:25
1424
Lunit Highlights the Effectiveness of AI in Acceleration of Immunotherapy Research--Findings to be Presented at SITC 2022
* Lunit to present three abstracts featuring Lunit SCOPE IO, the company's AI biomarker for immune phenotyping. * Lunit's presentations this year will highlight the effectiveness of Lunit SCOPE IO in accelerating immunotherapy clinical trials and drug development. SEOUL, South Korea, Nov. 7, ...
2022-11-07 21:00
1753
Week's Top Stories
Most Reposted
Earth Day 2024: Angel Yeast Continues to Tackle Plastic Pollution Challenges With Bio-based Material Solutions
[Picked up by 294 media titles]
2024-04-22 16:00
Trina Solar and PetroGreen Partner to Accelerate Philippine Solar Adoption with 117MW Supply Agreement
[Picked up by 291 media titles]
2024-04-22 06:00
Revenue Surpasses 50 Billion: BlueFocus Accelerates Towards the AI Native Era
[Picked up by 275 media titles]
2024-04-23 15:43
INTAMSYS Becomes 3D Printing Equipment Supplier for the WORLDSKILLS LYON 2024 COMPETITION
[Picked up by 273 media titles]
2024-04-24 17:09
Introducing Wacom Movink: The first OLED pen display, and the thinnest and lightest Wacom pen display ever
[Picked up by 268 media titles]
2024-04-24 13:00
Most Read
Automation Anywhere Appoints Tim McDonough as Chief Marketing Officer to Drive Global Awareness and Growth for the Leader in AI-Powered Automation
2024-04-24 03:57
5482
Earth Day 2024: Angel Yeast Continues to Tackle Plastic Pollution Challenges With Bio-based Material Solutions
2024-04-22 16:00
4443
Trina Solar and PetroGreen Partner to Accelerate Philippine Solar Adoption with 117MW Supply Agreement
2024-04-22 06:00
4034
TCTM Filed 2023 Annual Report on Form 20-F
2024-04-20 05:48
3294
Dingdong Files Its Annual Report on Form 20-F
2024-04-20 05:00
3039